Fueling Life is a podcast brought to you by — and all about — Diffusion Pharmaceuticals, an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen where it is needed most. This podcast will explore the science and ongoing studies of trans sodium crocetinate (TSC), our first-in-class, small molecule therapeutic that enhances the diffusion of oxygen to hypoxic tissues.
Analyzing TSC’s Impact on Carbon Monoxide Diffusion Through the Lungs
Diffusion’s Chief Medical Officer Dr. Chris Galloway provides an overview of the ILD-DLCO Trial, the third in a trio of Oxygenation Trials that will inform late-phase programs and clinical indications for lead drug candidate TSC.
15 Oct 2021
Evaluating the Effects of TSC on Maximal Oxygen Consumption
Chief Medical Officer Dr. Chris Galloway previews Diffusion’s Altitude Trial, the second in a trio of Oxygenation Trials that will collectively inform late phase programs and the clinical development plan for lead drug candidate TSC.
8 Oct 2021
Exploring TSC’s Impact on Tissue-Level Changes in Oxygen
Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.
2 Sept 2021
The Science of Solving for Hypoxia
In this episode, Diffusion Pharmaceuticals CEO Robert Cobuzzi, Jr., PhD discusses cellular oxygen deficiency, a condition known as hypoxia, outlines the company’s development plan, and highlights potential future applications for a small molecule therapeutic with a novel mechanism-of-action that enhances oxygen diffusion.
2 Sept 2021
Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals
Hypoxia, a potentially fatal shortage of oxygen in body tissue, is a serious and potentially fatal medical condition. In Fueling Life, a new podcast from Diffusion Pharmaceuticals, we’ll discuss how and why hypoxia occurs, and explore how Diffusion Pharmaceuticals’ lead product candidate, trans sodium crocetinate (TSC), represents a novel, targeted treatment opportunity to enhance the standard-of-care for conditions associated with hypoxia.
Contact Fueling Life
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Fueling Life?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
